



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Adnan M. M. Mjalli et al.
Serial No. : 10/091,609
Filing Date : March 5, 2002
For : BENZIMIDAZOLE DERIVATIVES AS
THERAPEUTIC AGENTS
Examiner : Unassigned
Art Unit : 1626

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

Election and Response

This Response is being submitted in response to the Office Action mailed April 15, 2003.


Claims 1-38 are pending in the present application. Applicants are required to elect one of the following inventions for further prosecution on the merits:

- I. Claims 1-24, drawn to products; and
- II. Claims 25-38, drawn to methods of use.

Applicants are also required to elect a single disclosed species for examination and to list claims readable thereon.

Applicants hereby elect, with traverse, Group I - Claims 1-24, drawn to products, for further prosecution on the merits.

Further, Applicants hereby elect the species 2-[(1R)-2-(4-(4-Chloro)phenoxy)phenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole for prosecution on the merits in the present application. This species is the compound described in Example 9. The structure of the elected species is shown below:



Claims 1, 2, and 11 read on the elected species.

Applicants traverse on the grounds that searching each group would not be unduly burdensome.

Respectfully submitted,

Date: May 6, 2003

Samuel B. Rollins
Samuel B. Rollins
Reg. No. 52,180

KILPATRICK STOCKTON LLP
1001 West Fourth Street
Winston-Salem, North Carolina 27101-2400
(336) 607-7432 Phone
(336) 734-2651 Facsimile

Attorney Docket No: 41305-271622